<DOC>
	<DOCNO>NCT01732627</DOCNO>
	<brief_summary>Primary objective : - To describe antibody response meningococcal serogroups A , C , Y , W-135 , measure serum bactericidal assay use human complement ( hSBA ) baby rabbit complement ( SBA-BR ) , induce single dose MenACYW conjugate vaccine Menomune® - A/C/Y/W-135 . - To describe safety profile single dose MenACYW conjugate vaccine Menomune® - A/C/Y/W-135 .</brief_summary>
	<brief_title>Study Quadrivalent Meningococcal Conjugate Vaccine Subjects Aged 56 Older</brief_title>
	<detailed_description>All participant receive single dose assigned vaccine Day 0 . They assess immunogenicity Day 30 , monitor safety throughout study .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 56 old day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure . Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination ) Participation time study enrollment ( 4 week precede trial vaccination ) plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede trial vaccination plan receipt vaccine 4 week follow trial vaccination except influenza vaccination , may receive least 2 week study vaccine Previous vaccination meningococcal disease either trial vaccine another vaccine Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History meningococcal infection , confirm either clinically , serologically , microbiologically At high risk meningococcal infection trial Known systemic hypersensitivity latex vaccine component , history severe reaction vaccine use trial vaccine containing substance Personal history GuillainBarré syndrome Personal history Arthuslike reaction vaccination tetanus toxoidcontaining vaccine within least 10 year propose study vaccination Selfreported thrombocytopenia , contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥ 100.4°F [ ≥ 38.0°C ] ) . A prospective subject include study condition resolve febrile event subside Receipt oral injectable antibiotic therapy within 3 day prior blood draw . Should subject receive oral injectable antibiotic therapy within 3 day prior blood draw , Investigator postpone blood draw 3 day since subject last received oral injectable antibiotic therapy . Postponement must still within timeframe blood draw indicate Table Study Procedures , possible Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcal Meningitis</keyword>
	<keyword>Menactra®</keyword>
	<keyword>Menomune® A/C/Y/W-135</keyword>
</DOC>